| Literature DB >> 35965546 |
Ruyue Liu1, Youhua Lu2, Yifan Li2, Wenjian Wei2, Chen Sun3, Qianqian Zhang4, Xin Wang5, Jialin Wang2, Nan Zhang2.
Abstract
Background: The low uptake rate of upper gastrointestinal cancer (UGC) screening substantially reduces the benefits of endoscopic screening. This study aimed to obtain residents' UGC screening preferences to optimize screening strategies and increase the participation rate.Entities:
Keywords: discrete choice experiment; endoscopic screening; preference; rural residents; upper gastrointestinal cancer
Year: 2022 PMID: 35965546 PMCID: PMC9363665 DOI: 10.3389/fonc.2022.917622
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
Attributes and levels for upper gastrointestinal cancer screening.
| Attributes | Levels | Definitions |
|---|---|---|
| Out-of-pocket costs | ¥0 | After receiving subsidies or insurance reimbursement, individuals pay the remaining screening fees. |
| ¥100 | ||
| ¥300 | ||
| ¥500 | ||
| Screening interval | Every year | Frequency of the endoscopy screening in an individual’s lifetime. |
| Every 2 years | ||
| Every 5 years | ||
| Once in a lifetime | ||
| Regular follow-up for precancerous lesions | Yes | Regular follow-up is provided or not for precancerous lesions such as gastritis, intraepithelial neoplasia, and dysplasia. |
| No | ||
| Mortality reduction | 15% | The extent to which an individual’s risk of death is reduced after participating in endoscopic screening. |
| 30% | ||
| 45% | ||
| 60% | ||
| Screening technique | Endoscopy | Endoscopy or painless(anesthesia) endoscopy screening test. |
| Painless (anesthesia) endoscopy |
Characteristics of the respondents.
| Characteristics | Respondents | Non-respondents |
|
| ||
|---|---|---|---|---|---|---|
| n = 926 (who passed the consistency test) | n = 33 (who failed the consistency test) | |||||
| n | No. (%) | n | No. (%) | |||
| Mean age, years (SD) | 57.32 (7.22) | 57.36 (7.17) | − | − | ||
| Gender | ||||||
| Male | 315 | 34.02 | 12 | 36.36 | 0.078 | 0.780 |
| Female | 611 | 65.98 | 21 | 63.64 | ||
| Age | ||||||
| 40-49 | 139 | 15.01 | 1 | 3.03 | 4.308a | 0.095 |
| 50-59 | 414 | 44.71 | 19 | 57.58 | ||
| 60-70 | 373 | 40.28 | 13 | 39.39 | ||
| Marital statusb | ||||||
| With a partner | 888 | 95.90 | 30 | 90.91 | 1.937a | 0.163 |
| Without a partner | 38 | 4.10 | 3 | 9.01 | ||
| Annual family income (RMB) | ||||||
| <10,000 | 434 | 46.87 | 21 | 63.64 | 3.917 | 0.141 |
| 10,000-29,999 | 294 | 31.75 | 6 | 18.18 | ||
| ≥30,000 | 198 | 21.38 | 6 | 18.18 | ||
| Location c | ||||||
| Linqu | 322 | 34.77 | 11 | 33.33 | 0.328 | 0.849 |
| Feicheng | 310 | 33.48 | 10 | 30.31 | ||
| Dongchangfu | 294 | 31.75 | 12 | 36.36 | ||
| Family history of cancer d | ||||||
| Yes | 183 | 19.76 | 3 | 9.09 | 2.321 | 0.128 |
| No | 743 | 80.24 | 30 | 90.91 | ||
| Screening for cancer | ||||||
| Ever | 520 | 56.16 | 11 | 33.33 | 6.716 | 0.010 |
| Never | 406 | 43.84 | 22 | 66.67 | ||
:aFisher exact probability method. bMarital status: with a partner, reflecting that the individual is married and the spouse is alive; without a partner, including single, divorced, widowed. cThe per capita GDP in 2020 in Linqu, Feicheng, and Dongchangfu were ¥39,910, ¥80,696, and ¥50,726, respectively. dHistory of cancer in blood relatives, including parents, grandparents, siblings, uncles, aunts, cousins. RMB, the average exchange rate between US$ and RMB in 2021 was US$1 = RMB 6.45; SD, standard deviation.
Preference and WTP results of a mixed logit model.
| Attributes and levels | Mean (preference) | SD (preference) | WTP | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
| 95% CI |
|
| 95% CI |
|
| 95% CI | |
| ASC (Opt-out) | -6.829** | -9.490 | (-8.238, -5.419) | 6.826** | 12.000 | (5.711, 7.941) | − | − | − |
| Screening interval | |||||||||
| Once in a lifetime (Ref) | |||||||||
| Every year | 1.184** | 13.560 | (1.013, 1.355) | 0.645** | 4.370 | (0.356, 0.934) | 277.48** | 12.260 | (233.14, 321.82) |
| Every 2 years | 1.122** | 11.600 | (0.933, 1.132) | 0.392 | 1.500 | (-0.120,0.905) | 263.01** | 10.690 | (214.79, 311.22) |
| Every 5 years | 0.971** | 9.220 | (0.764, 1.177) | 0.687** | 3.150 | (0.260, 1.115) | 227.50** | 9.840 | (182.17, 272.82) |
| Regular follow-up for precancerous lesions | |||||||||
| Yes (Ref) | |||||||||
| No | -0.243** | -4.820 | (-0.342, -0.144) | 0.010 | 0.090 | (-0.198, 0.218) | -57.02** | -4.770 | (-80.46, -33.58) |
| Mortality reduction | |||||||||
| 15% (Ref) | |||||||||
| 30% | 0.068 | 0.760 | (-0.107, 0.243) | 0.013 | 0.100 | (-0.254, 0.229) | 15.96 | 0.760 | (25.16, 57.08) |
| 45% | 0.225* | 2.170 | (0.022, 0.427) | 0.010 | 0.020 | (-0.806, 0.786) | 52.63* | 2.140 | (4.49, 100.77) |
| 60% | 0.191* | 2.330 | (0.030, 0.352) | 0.411* | 2.060 | (0.020, 0.801) | 44.81* | 2.300 | (6.65, 82.97) |
| Screening technique | |||||||||
| Endoscopy (Ref) | |||||||||
| Painless (anesthesia) endoscopy | 2.927** | 19.810 | (2.638, 3.217) | 2.245** | 17.010 | (1.987, 2.504) | 686.01** | 17.22 | (607.92, 764.10) |
| Out-of-pocket costs | -0.004** | -16.010 | (-0.005, -0.004) | 0.003** | 11.300 | (0.003, 0.004) | − | − | − |
| Sample | 926 | ||||||||
* P< 0.05, * * P< 0.01; ASC (Opt-out), a specific constant item for opt-out; Ref, reference, which reflects a reference level in each attribute; β, which reflects the values of each attribute level and the horizontal regression coefficient; WTP, willingness to pay, which reflects residents’ willingness to pay for a certain screening program; SD, standard deviation; SE, standard error; 95% CI, 95% confidence interval.
The results of different subgroup analysis and WTP(β(WTP)).
| Attributes | Location | Age | Gender | Annual family income (RMB) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Linqu (n=322) | Feicheng (n=310) | Dongchangfu (n=294) | 40-49(n=139) | 50-59(n=414) | 60-69(n=373) | Male(n=315) | Female(n=611) | <10000(n=434) | 10000-29999(n=294) | ≥30000(n=198) | |
| ASC (Opt-out) | -3.717** | -6.304** | -7.375** | -5.512** | -6.826** | -8.728** | -5.529** | -8.062** | -7.501** | -9.067** | -3.611** |
| Screening interval | |||||||||||
| Once in a lifetime (Ref) | |||||||||||
| Every year | 1.487**
| 1.155**
| 1.023**
| 2.032**
| 1.456**
| 0.754**
| 1.341**
| 1.119**
| 0.875**
| 1.166**
| 2.201**
|
| Every 2 years | 1.718**
| 1.153**
| 0.604**
| 2.131**
| 1.336**
| 0.681**
| 1.329**
| 1.028**
| 0.838**
| 1.143**
| 1.979**
|
| Every 5 years | 1.089**
| 1.007**
| 0.790**
| 1.924**
| 0.873**
| 0.854**
| 0.978**
| 0.964**
| 0.823**
| 0.925**
| 1.657**
|
| Regular follow-up for precancerous lesions | |||||||||||
| Yes (Ref) | |||||||||||
| No | -0.254*
| -0.256**
| -0.285*
| -0.096 | -0.329**
| -0.231**
| -0.244**
| -0.239**
| -0.276**
| -0.341**
| -0.087 |
| Mortality reduction | |||||||||||
| 15% (Ref) | |||||||||||
| 30% | 0.015 | 0.153 | 0.024 | 0.162 | 0.059 | 0.075 | 0.103 | 0.072 | 0.215 | 0.063 | -0.241 |
| 45% | 0.151 | 0.161 | 0.431*
| 0.453 | 0.292 | 0.141 | 0.333 | 0.182 | 0.359*
| 0.224 | -0.022 |
| 60% | 0.052 | 0.411 | 0.077**
| 0.367 | 0.186 | 0.144 | 0.400**
| 0.086 | 0.049 | 0.360**
| 0.275 |
| Screening technique | |||||||||||
| Endoscopy (Ref) | |||||||||||
| Painless (anesthesia) endoscopy | 4.542**
| 2.078 | 3.037**
| 3.439**
| 3.046**
| 3.013**
| 2.734**
| 3.088**
| 3.217**
| 2.707**
| 3.445**
|
| Out-of-pocket costs | -0.006** | -0.004 | -0.004** | -0.004** | -0.004** | -0.005** | -0.004** | -0.004** | -0.006** | -0.004** | -0.003** |
* P< 0.05, * * P< 0.01. A separate regression is run for each subgroup. The baseline job is the same in all regressions. a The per capita GDP in 2020 in Linqu, Feicheng, and Dongchangfu were ¥39,910, ¥80,696, and ¥50,726, respectively. ASC (Opt-out), a specific constant item for opt-out; Ref, reference, which reflects a reference level in each attribute; β, which reflects the values of each attribute level and the horizontal regression coefficient; WTP, willingness to pay, which reflects residents’ willingness to pay for a certain screening program; 95% CI, 95% confidence interval; RMB, US$ 1 = RMB 6.45.
Figure 1Effects of changing the screening program characteristics on the probability of participation in upper gastrointestinal cancer screening. UGC, upper gastrointestinal cancer.
Figure 2The participation rates for UGC screening at different levels of out-of-pocket costs. Baseline: once in a lifetime, with follow-up, a 15% mortality reduction, and endoscopy; UGC, upper gastrointestinal cancer; OOP, out-of-pocket.